ArticleFrontiers in medicine2025
Monoclonal antibodies in severe asthma: outcomes from real-world data.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uncontrolled severe asthma represents a substantial clinical and economic burden, particularly in patients with comorbidities and poor response to high-dose inhaled corticosteroids. Monoclonal antibodies targeting type 2 (T2) inflammation have become key therapeutic options, but their real-world performance remains insufficiently characterized. Objective: To evaluate the real-world effectiveness, adherence, and persistence of benralizumab, mepolizumab, omalizumab, and reslizumab in adults with uncontrolled severe asthma after 12 months of treatment. Methods: A retrospective real-world observational study was conducted in patients with uncontrolled severe asthma who initiated treatment with benralizumab, mepolizumab, omalizumab, and reslizumab between January 2015 and December 2022. Clinical, functional, and laboratory outcomes were assessed at baseline and after 12 months, including eosinophil count, forced expiratory volume in 1 s (FEV Results: A total of 154 patients (188 treatment episodes) were included. The median follow-up was 2.2 years (IQR 1.3-4.2). All monoclonal antibodies were associated with significant improvements in asthma control at 12 months. Blood eosinophil counts declined across all therapies, with near-complete depletion observed in patients treated with benralizumab and reslizumab. Median ACT scores increased by six points, and FEV₁ improved by 7%. Annual exacerbation rates and healthcare utilization decreased significantly across all groups. Adherence was high (95%), and the median treatment persistence was 2.0 years (IQR 1.4-4.1). Overall, 42% of patients discontinued treatment, mainly due to insufficient clinical response (48.4%) or drug supply issues (42.2%). Conclusion: In routine clinical practice, benralizumab, mepolizumab, omalizumab, and reslizumab were associated with improvements in asthma control, lung function, and reduction in exacerbations over 12 months. Benralizumab and reslizumab were associated with the greatest reductions in eosinophil counts. Our findings suggest comparable effectiveness across biologics. High adherence and treatment persistence support their feasibility in real-world settings. These results underscore the relevance of phenotype-driven therapy selection and highlight the need for long-term monitoring to optimize outcomes in severe asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.